31 related articles for article (PubMed ID: 29952517)
1. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
Song W; Kwon GY; Kim JH; Lim JE; Jeon HG; Il Seo S; Jeon SS; Choi HY; Jeong BC; Lee HM
Oncotarget; 2016 Dec; 7(50):83735-83743. PubMed ID: 27863438
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
[TBL] [Abstract][Full Text] [Related]
4. The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.
Park JC; Pratz CF; Tesfaye A; Brodsky RA; Antonarakis ES
Clin Genitourin Cancer; 2015 Feb; 13(1):32-8. PubMed ID: 24999166
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.
Fernando M; Anton A; Weickhardt A; Azad AA; Uccellini A; Brown S; Wong S; Parente P; Shapiro J; Liow E; Torres J; Goh J; Parnis F; Steer C; Warren M; Gibbs P; Tran B
J Geriatr Oncol; 2023 Nov; 14(8):101621. PubMed ID: 37683368
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer.
de Liaño AG; Reig O; Mellado B; Martin C; Rull EU; Maroto JP
Br J Cancer; 2014 Apr; 110(9):2201-8. PubMed ID: 24722180
[TBL] [Abstract][Full Text] [Related]
7. Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies.
Wenzel M; Preisser F; Hoeh B; Schroeder M; Würnschimmel C; Steuber T; Heinzer H; Banek S; Ahrens M; Becker A; Karakiewicz PI; Chun FKH; Kluth LA; Mandel P
Front Oncol; 2021; 11():659135. PubMed ID: 33968764
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.
Nixon AB; Liu Y; Yang Q; Luo B; Starr MD; Brady JC; Kelly WK; Beltran H; Morris MJ; George DJ; Armstrong AJ; Halabi S
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38347114
[TBL] [Abstract][Full Text] [Related]
9. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.
Francini E; Petrioli R; Rossi G; Laera L; Roviello G
Tumour Biol; 2014 Nov; 35(11):10601-7. PubMed ID: 25195134
[TBL] [Abstract][Full Text] [Related]
10. Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies.
Ghatalia P; Pond GR; Templeton AJ; Sonpavde G
Clin Genitourin Cancer; 2018 Apr; 16(2):e277-e287. PubMed ID: 29352714
[TBL] [Abstract][Full Text] [Related]
11. Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer.
Bejrananda T; Pripatnanont C; Tanthanuch M; Karnjanawanichkul W
J Med Assoc Thai; 2016 Dec; 99(12):1315-21. PubMed ID: 29952517
[TBL] [Abstract][Full Text] [Related]
12. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
14. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
